Profile
Settings
Refer your friends
Sign out
Why in News?
- AstraZeneca, the maker of Covishield has acknowledged that its vaccine could cause blood clots in “very rare” cases.
- This acknowledgment comes as part of ongoing legal proceedings in the UK, where individuals have reported severe health issues post-vaccination.
Key Details:
- Background: Developed during the COVID-19 pandemic, Covishield is the Indian version of AstraZeneca’s AZD1222 vaccine, manufactured by the Serum Institute of India.
- Legal Case: The company’s admission emerged in a UK court case, where a claimant suffered a severe brain injury caused by Thrombosis with Thrombocytopenia Syndrome linked to a vaccine-induced blood clot.
- WHO’s Stance: The World Health Organization has pointed out that the risk of TTS is very low but noticeable, with incidence rates varying across regions.
Thrombosis with Thrombocytopenia Syndrome (TTS):
- Definition: Thrombosis with Thrombocytopenia Syndrome (TTS) involves blood clots and a low platelet count.
- Symptoms: Include breathlessness, chest pain, persistent headaches, and unusual skin marks near the injection site.
